Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.

@article{Yuen2012CombinationOT,
  title={Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.},
  author={John Shyi Peng Yuen and Mei Yi Sim and Hong Gee Sim and Tsung Wen Chong and Weber Kam On Lau and Christopher Wai Sam Cheng and Richard Weijie Ong and Hung Quoc Huynh},
  journal={International journal of oncology},
  year={2012},
  volume={41 2},
  pages={712-20}
}
Sorafenib, a multikinase inhibitor, is currently used as monotherapy for advanced renal cell carcinoma (RCC). However, adverse effects associated with its use have been experienced by some patients. In this study, we examined the antitumor and antiangiogenic activities of low-dose sorafenib in combination with the MEK inhibitor AZD6244 (sorafenib/AZD6244) in a preclinical model of RCC. Primary RCC 08-0910 and RCC 786-0 cells as well as… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Xenografts of human hepatocellular carcinoma: a useful model for testing drugs.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2006

Similar Papers

Loading similar papers…